In May 2016, the first case of colistin-resistant Escherichia coli (mcr-1) infection was found in the USA, revealing the possibility of the emergence of truly-pan drug resistance 2 . Furthermore, the overuse of colistin in animal led to the release of a recommendation from European Medicines Ageney to set a goal of 65% reduction in colistin use in agriculture 3 . In the University Medical Center HCMC, the total colistin consumption in 2016 increased dramatically compared to the year 2015. This study was thus conducted to investigate colistin use, to evaluate rational colistin indication and to identify potential risk factors for colistin-induced nephrotoxicity.
MATERIAL AND METHODS

Study population
Data was obtained from all in-patients who were indicated colistin for 72 hours or more from January 1 st 2016 to December 31 st 2016 . If a patient received more than one course of colistin therapy, data was only collected from the first course. One hundred and two medical profiles met the criteria were enrolled in this study. The study protocol was scrutinized and approved by ethical committee of UMC prior to data collection.
Methods
A descriptive cross-sectional study was conducted to provide information on demographics, causative organisms, antimicrobial treatment, outcome and nephrotoxicity. Colistin use is determined as "rational" when all these criteria are met:
• Gram-negative bacteria from collected sample were isolated before colistin indication 4* .
• The organisms was susceptible only to colistin * .
• If intravenous colistin was indicated, another antibiotic or inhaled colistin should be concurrently indicated 5, 6 .
• Inhaled colistin monotherapy was determined as irrational use. Inhaled colistin should be combined with intravenous colistin 4, 6 .
• Rational dosing using FDA recommendation 7, 8 . 
RESULTS
Characteristics of the study population
The median age of the study population was 77.5. Patients aged above 75 constituted more than half (53.9%) and 64.7% of the population was male. The mean body weight of the study population was 48.2 ± 19.5 kg, ranging from 3.5 to 85 kg. The ICU (61.8%), respiratory department (14.8%) and cardiac surgery department (12.7%) accounted for the most cases of colistin use. Cardiovascular diseases (70.6%) were the most common comorbid disease and 90.2% of patients experienced at least one comorbid disease. Endotracheal intubation (72.5%) was the most popular invasive procedure performed prior to colistin indication. The average length of hospital stay observed was 45.1 ± 31.3 days, ranging from 9 to 213. Pneumonia (77.5%) was the most common cause of colistin indication. The characteristics of the study population were presented in Table 1 .
Microbiologic characteristics
Bacterial pathogens
Of 102 medical records collected, microbial testing was performed in 98 cases Distribution of bacterial pathogens isolated by specimens was presented in figure 1.
Antibiotic resistance
Results from antibiograms showed that antibiotic resistance varied among different microbes, but no colistin-resistant pathogen was found in the study population. More than 80% of the multi-resistant bacteria isolated were resistant to all second and third-generation cephalosporin (except cefoperazone/sulbactam), carbapenem, netilmicin and fluoroquinolones. A. baumanii was resistant at a low rate to cefoperazone/sulbactam (12.7%) while piperacillin/ tazobactam showed a low resistance proportion in Pseudomonas (34.8%). Amikacin and cefoperazone/sulbactam remained highly effective to K. pneumoniae and E. coli. Resistance to antibiotics tested of the multi-resistant bacteria isolated was illustrated in Figure 2 . 
Antibiotic therapy
Empiric antibiotic before colistin use
Within 10 days prior to colistin therapy, 97.1% patients in the study population received at least one antibiotic orally or intravenously. Meropenem (21.8%), levofloxacin (15.3%) and teicoplanin (10.2%) were the most frequently antibiotic empirically prescribed.
Concurrent antibiotic use
The combination of two antibiotics, three antibiotics and four antibiotics was observed in 43.1%, 34.9% and 9.8% of the study population, respectively. Colistin plus cefoperazone/sulbactam was the most frequently combination administered (37.0%), followed by meropenem (23.0%), piperacillin/tazobactam (6.7%) and teicoplanin (6,7%).
Colistin use
The combination of inhaled and intravenous colistin was indicated in 56.8% of the study population. Intravenous colistin monotherapy and inhaled colistin monotherapy was indicated in 32.4 and 8.8% of the study population, respectively. Only two patients received intrathecal colistin (2.0%).
Loading dose was observed in 9 cases (8.8%). The average cumulative colistin dose during the course of treatment was 54.8 ± 34.4 MIU and patients received 97.26 ± 35.21 IU colistin intravenously on average. The mean duration of colistin therapy was 13.1 ± 6.7 days, ranging from 3 to 40 days.
When compared to FDA guidelines, it is shown that among patients with clearance creatinine greater than 80 mL per minute, colistin dose was rationally indicated (100%). However, the rationality decreased to 45.2% in patients with clearance creatinine between 50 and 80 mL per minute and 4.2% in patients with clearance creatinine less than 50 mL per minute ( 
Rationality of colistin indication
Only 32.8% of cases was found to be rationally indicated. Cases estimated as "irrational use" were classified as followed: (1) Multivariable logistic regression showed that no significantly statistical association was found between rational colistin use and age, gender, clinical department, infectious disease diagnosed, type of comorbidity, number of comorbidities and length of stay.
Treatment outcome
At hospital discharge, only 2% of the study population was recovered, 47.5% was reported as "improved", 15.9% remained unchanged and deterioration was seen in 35.6% of the study population.
Nephrotoxicity
After the course of treatment, there was a significant decrease in the average clearance creatinine. (p < 0.05). Twenty one patients (22.8%) had preexisting renal failure prior to the administration of colistin, defined by serum creatinine (SCr) above 1.2 mg/dL (Table 3) . Nephrotoxicity during colistin treatment was observed in 33 patients (35.5%) using RIFLE criteria. 
Factors associated with nephrotoxicity
DISCUSSION
The length of stay observed in this study varied widely from 9 to 213 days. This can be explained by the fact that a majority of the population with multiple comorbidities was admitted to Intensive Care Unit. Moreover, late onset hospital-acquired infections could be associated with multi-drug resistant organisms and empiric antibiotic could be ineffective, leading to prolonged hospital stay.
Results from our study showed a considerably high proportion of irrational colistin use in the study population. Although no case of resistance to colistin was observed during the study period, such high proportion of irrational use might lead to the development of resistance to colistin through adaptation. Guidelines for colistin use should be established and strictly followed to prevent resistance to this last-resort antibiotic.
The dose recommendations for colistin differ among guidelines, especially FDA and EMA-approved recommendations. In this study, we compared daily dose per kilogram to the FDA-approved dose recommendations since the EMA-approved doses were considerably higher than those recorded from our study. However, a study conducted by Nation RL showed that average steady state concentrations could only be achieved by EMA -approved regimen and the other regimens did not provide adequate concentration 7 . Further studies need to be conducted to assess the efficacy and toxicity of different dosing regimens to establish a standard dose recommendation for UMC as well as other hospitals in Vietnam.
Microbial testing was performed in only 39.2% patients after 5 days using colistin. Microbiological outcome, therefore, was not reported in the study.
Nephrotoxicity was observed in 35.5% of the study population using RIFLE criteria, which was comparable to previous studies. The previously reported incidences of nephrotoxicity varied widely from 0 to 76% 9 . Four contributing factors to nephroxicity included age, respiratory diseases, concomitant use with furosemide or amphotericin B. These findings were also similar to the results from previous reports. According to Koksal I, age was positively correlated with nephrotoxicity 10 . The majority of patients in this study population aged 60 or over and nephrotoxicity was observed in 41.8% of patients in this group while only 19.2% of patients under-60 experienced the event. The study by Montero M. concluded that respiratory diseases were attributable to nephrotoxicity 11 . Although results from this study showed that the presence of asthma, COPD or other respiratory diseases decreased the risk of renal injury, findings from the study by Montero M revealed the opposite. No statistical association was found between colistin dose and nephrotoxicity was observed in this study though it was found in previous study by Deryke CA. 12 Concurrent use with other nephrotoxic agents such as furosemide and amphotericin B was reported in previous studies by Deryke and Sorli L 12, 13 .
In patients with multiple comorbidities, the use of these agents sometimes is unavoidable.
Thus, all these factors should be taken into consideration when colistin is indicated and renal function should be frequently monitored.
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